Target–drug interactions: first principles and their application to drug discovery (Q37903454)

25 August 2017

0 references

1 reference

title

Target-drug interactions: first principles and their application to drug discovery (English)

1 reference

25 August 2017

Target–drug interactions: first principles and their application to drug discovery (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

7 December 2024

1 reference

Jennifer Venhorst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21777691

7 December 2024

Sara Núñez

1 reference

25 August 2017

Chris G. Kruse

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21777691

7 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21777691

7 December 2024

publication date

12 July 2011

1 reference

full work available at URL

25 August 2017

https://api.elsevier.com/content/article/PII:S1359644611002133?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

https://api.elsevier.com/content/article/PII:S1359644611002133?httpAccept=text/plain

7 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

7 December 2024

1 reference

25 August 2017

1 reference

25 August 2017

issue

1-2

1 reference

25 August 2017

page(s)

10-22

1 reference

Biochemical mechanisms of drug action: what does it take for success?

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Can the pharmaceutical industry reduce attrition rates?

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Drug-target residence time and its implications for lead optimization

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The role of binding kinetics in therapeutically useful drug action

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Residence time of receptor-ligand complexes and its effect on biological function

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Drug-target residence time: critical information for lead optimization.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Surface plasmon resonance: a general introduction

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Survey of the year 2006 commercial optical biosensor literature

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Relationships between structure and interaction kinetics for HIV-1 protease inhibitors

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Update of KDBI: Kinetic Data of Bio-molecular Interaction database.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

7 December 2024

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Slow antagonist dissociation and long-lasting in vivo receptor protection

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The Interaction between alpha-Chymotrypsin and Pancreatic Trypsin Inhibitor (Kunitz Inhibitor). Kinetic and Thermodynamic Properties

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Adaptive inhibitors of the HIV-1 protease

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Overcoming roadblocks in lead optimization: a thermodynamic perspective

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Calorimetry and thermodynamics in drug design

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Enthalpy-entropy compensation: a phantom phenomenon

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Thermodynamic contributions of the ordered water molecule in HIV-1 protease

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

High-energy water sites determine peptide binding affinity and specificity of PDZ domains

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Adding calorimetric data to decision making in lead discovery: a hot tip

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Measurements of binding thermodynamics in drug discovery

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

On the value of c: can low affinity systems be studied by isothermal titration calorimetry?

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

ITC in the post-genomic era...? Priceless

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Isothermal titration calorimetry to determine association constants for high-affinity ligands

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Binding thermodynamics of statins to HMG-CoA reductase

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Water, water everywhere--except where it matters?

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

A thermodynamic approach to the affinity optimization of drug candidates

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The Thermodynamics of Protein–Ligand Interaction and Solvation: Insights for Ligand Design

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Application and limitations of X-ray crystallographic data in structure-based ligand and drug design

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Protein Structure and the Energetics of Protein Stability.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

The enthalpy change in protein folding and binding: refinement of parameters for structure-based calculations.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Novel method for probing the specificity binding profile of ligands: applications to HIV protease

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Do enthalpy and entropy distinguish first in class from best in class?

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Compensating enthalpic and entropic changes hinder binding affinity optimization

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Isothermal titration calorimetry: controlling binding forces in lead optimization

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Multidrug Resistance to HIV-1 Protease Inhibition Requires Cooperative Coupling between Distal Mutations

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands.

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations

7 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.DRUDIS.2011.06.013

7 December 2024

Identifiers

1 reference

25 August 2017

1 reference